US2015374805A1PendingUtilityA1
Use of botulinum toxin therapy for treatment of urological neurological conditions
Est. expiryJul 15, 2017(expired)· nominal 20-yr term from priority
Inventors:Richard A. Schmidt
A61P 25/00A61K 31/353A61K 31/16A61P 15/00A61P 13/10C12Y 304/24069A61K 38/4893
57
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention relates to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin.
Claims
exact text as granted — not AI-modified1 - 9 . (canceled)
10 . A method for reducing pelvic pain in a patient in need thereof, the method comprising administering a botulinum toxin to the bladder of the patient, thereby reducing the pelvic pain.
11 . The method of claim 10 , wherein the patient is a human.
12 . The method of claim 10 , wherein the botulinum toxin is a botulinum toxin type A.
13 . The method of claim 10 , wherein the botulinum toxin is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a cream, an emulsion, a suspension, and a solution.
14 . The method of claim 10 , wherein the botulinum toxin is administered in an amount of up to 2500 units.
15 . The method of claim 10 , wherein the botulinum toxin is administered in an injectable, pharmaceutically acceptable formulation selected from the group consisting of a liquid, a cream, an emulsion, a suspension, and a solution.
16 . A method for reducing pelvic pain in a patient in need thereof, the method comprising administering a botulinum toxin type A; in an amount of up to 2500 units, to the urinary tract of the patient, thereby reducing the pelvic pain.
17 . The method of claim 16 , wherein the patient is a human.
18 . The method of claim 16 , wherein the botulinum toxin type A is administered in a pharmaceutically acceptable formulation selected from the group consisting of: a liquid, a cream, an emulsion, a suspension, and a solution.
19 . The method of claim 16 , wherein the botulinum toxin is administered in an injectable, pharmaceutically acceptable formulation selected from the group consisting of a liquid, a cream, an emulsion, a suspension, and a solution.Join the waitlist — get patent alerts
Track US2015374805A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.